Ginkgo Bioworks Holdings, INC

Ginkgo Bioworks Holdings, Inc. announced the date for its second quarter 2026 financial results presentation and Q&A session.

Ginkgo Bioworks shareholders re-elected the board of directors and ratified the appointment of Deloitte & Touche LLP.

Ginkgo Bioworks announced its first quarter 2026 financial results, reporting $19 million in revenue and a GAAP net loss of $76 million, while also completing the divestiture of its Biosecurity business.

Ginkgo Bioworks Holdings, Inc. has completed the sale of its Biosecurity segment to Tower Biosecurity, Inc., receiving approximately 20% equity in the purchaser.

Ginkgo Bioworks Holdings, Inc. is divesting its Biosecurity segment to Tower Biosecurity, Inc. in exchange for a 20% equity stake in the new entity.

Ginkgo Bioworks announced its Q4 and full year 2025 financial results, revealing a strategic pivot towards autonomous labs and the divestiture of its biosecurity business.

Ginkgo Bioworks Holdings, Inc. reported a significant revenue decrease in Q3 2025 and for the nine months ended September 30, 2025, as it continues its comprehensive restructuring plan.

Ginkgo Bioworks Holdings, Inc. reported a significant reduction in net and operating losses for Q2 and H1 2025, driven by ongoing restructuring efforts and expense reductions, despite a decline in Biosecurity revenue.

Ginkgo Bioworks' Q1 2025 revenue increased due to a one-time revenue recognition from the BiomEdit contract termination, while the company continues to manage restructuring and cost-saving initiatives.

Ginkgo Bioworks saw a significant increase in Cell Engineering revenue in Q3 2024, while also reporting a net loss and restructuring charges.

Ginkgo Bioworks reported a net loss of $217.2 million for Q2 2024, alongside a restructuring plan aimed at reducing operational expenditures.

Ginkgo Bioworks' first quarter 2024 results show a decrease in revenue compared to the same period last year, driven by a strategic shift in its biosecurity business and timing of cell engineering programs.

Ginkgo Bioworks Holdings, Inc. reported a significant reduction in its net loss for 2025, reaching $(312.8) million, despite a decrease in total revenue to $170.2 million, as the company continues its strategic restructuring and focuses on its core cell engineering platform.

Ginkgo Bioworks' FY24 results highlight a strategic shift towards cell engineering and biosecurity, amidst restructuring and operational changes.

Ginkgo Bioworks outlines the specifics of its multi-class capital stock structure, including voting rights, economic rights, and conversion options, in a recent SEC filing.

Barry Canton, a 10% owner of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Reshma P. Shetty, See remarks, a Director and 10% owner of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Jason R Kelly, See remarks and a Director of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Steven P. Coen, See remarks of Ginkgo Bioworks Holdings, Inc., sold 752 shares of common stock on July 16, 2026 for $7.90 per share.

Ginkgo Bioworks Director Christian O. Henry received a grant of 25,000 Restricted Stock Units as part of the company's non-employee director compensation program.

Ginkgo Bioworks Holdings, Inc. reports that Director Ross Fubini was granted 25,000 Restricted Stock Units (RSUs) on June 11, 2026, with vesting conditions tied to continued service.

Ginkgo Bioworks Holdings, Inc. has filed a definitive proxy statement with the SEC.

Ginkgo Bioworks will hold its 2025 Annual Meeting of Shareholders virtually on June 12, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.

Ginkgo Bioworks issues a supplement to its proxy statement to correct an error in the description of the voting standard for the reverse stock split proposal.

Ginkgo Bioworks is asking shareholders to approve a reverse stock split, officer exculpation, and charter updates at a special meeting on August 14, 2024.

Ginkgo Bioworks nominates Myrtle Potter and Ross Fubini as independent directors while Marijn Dekkers and Reshma Kewalramani will retire from the board at the upcoming annual meeting on June 13, 2024.

Ginkgo Bioworks will hold its 2024 Annual Meeting of Shareholders virtually on June 13, 2024, to vote on director elections, ratification of the independent auditor, and executive compensation.

Ginkgo Bioworks Holdings, Inc. founders Reshma P. Shetty and Barry Canton have updated their beneficial ownership stake to 9.5% of Class A Common Stock following the company's one-for-forty reverse stock split in August 2024.

BlackRock, Inc. has amended its Schedule 13G filing to report its beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A Stock.

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group regarding Ginkgo Bioworks.

The Vanguard Group has filed an amended Schedule 13G, indicating a 0% beneficial ownership in Ginkgo Bioworks Holdings Inc. following an internal realignment.

Baillie Gifford & Co. reported a 4.9% beneficial ownership stake in Ginkgo Bioworks Holdings, Inc.'s Class A Common Stock as of December 31, 2025.

Cascade Investment, L.L.C. and William H. Gates III have reported a 7.5% beneficial ownership stake in Ginkgo Bioworks Holdings, Inc., including potential earn-out shares.

The Vanguard Group has reported a 5.13% beneficial ownership stake in Ginkgo Bioworks Holdings Inc., primarily for investment purposes.